Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...
Iron metabolism imbalance and ferroptosis are central to PF pathogenesis, offering new therapeutic targets. Ferroptosis links oxidative stress, iron overload, and fibrotic remodeling, affecting key ...
Idiopathic pulmonary fibrosis (IPF) is a chronic disease in which healthy lung tissue is gradually replaced by scar tissue. While the early events that initiate this change are poorly understood, ...
Hosted on MSN
Pulmonary fibrosis: Nerandomilast inhibits phosphodiesterase 4B, may treat multiple forms of disease
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...
Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results